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Abstract The interaction of L-arrestin-1 with the somatostatin
receptor type 2A (sst2A) was monitored using both biochemical
and confocal imaging approaches. We show that, using transient
transfection of either L-arrestin-1 or its dominant negative
v-arrestin-1 in CHO cells stably transfected with the sst2A,
L-arrestin-1 is colocalized with the receptor in endosomal vesicles
after somatostatin-induced sequestration. However, this interac-
tion leads to a role of L-arrestin-1 in the desensitization of the
sst2A rather than in the internalization process of the receptor^
ligand complex. ß 2002 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Somatostatin (somatotropin release inhibitory factor,
SRIF) exerts endocrine, exocrine and neuronal functions
through activation of six known G protein-coupled receptors
(GPCR) (sst1, sst2A, sst2B, sst3, sst4 and sst5) [1,2]. All these
receptors couple to Gi/Go proteins and are able to internalize
with various e⁄ciencies after binding of the peptide [3,4].
Signal transduction mechanisms activated by SRIF^receptor
interaction involve both pertussis toxin-sensitive and -insensi-
tive G proteins. Thus, the inhibition of adenylate cyclase and
Ca2 channels as well as the stimulation of K channels,
phospholipase C, phosphatases, arachidonic acid release,
and mitogen-activated protein kinases observed after activa-
tion of sst receptors are inhibited by pertussis toxin [5^12],
whereas inhibition of the SRIF-induced Na/H exchange is
insensitive to the toxin [13].
A common property of most GPCRs is that ligand treat-
ment decreases receptor responsiveness through a mechanism
called desensitization. Receptor desensitization as well as re-
ceptor internalization is often mediated by arrestins. The
phosphorylation of agonist-stimulated GPCRs by G protein-
coupled receptor kinases (GRK) leads to the binding of ar-
restins [14]. Arrestins also interact with clathrin heavy chain
to induce GPCR internalization via clathrin-coated pits [15].
The role of L-arrestin-1 (also called arrestin-2) in the internal-
ization process has been argued using the L2-adrenergic re-
ceptor: overexpression of L-arrestin-1 increases receptor inter-
nalization [15] whereas dominant negative arrestin mutants
that selectively bind to clathrin inhibit agonist-induced seques-
tration of the L2-adrenergic receptor [16]. By contrast, inter-
nalization of the muscarinic m2 receptor has been shown to be
arrestin-independent although the receptor is phosphorylated
by GRKs, binds arrestins and desensitizes [17]. Interestingly,
GPCRs were also able to bind the adapter protein AP2 that
could serve as a substitute for L-arrestin in clathrin-mediated
endocytosis [18]. This raises the question of the exact relation-
ships between internalization and desensitization for which
arrestins may play either a common or a dissociated role.
Recent studies have shown that sst2A e⁄ciently desensitizes
upon SRIF treatment [19] and that the desensitization mech-
anism involves interaction with arrestins [20]. However, a di-
rect involvement of L-arrestin-1 in sst2A internalization or
desensitization was not established. In this work, we demon-
strate that the interaction of L-arrestin-1 with the sst2A re-
ceptor expressed in CHO cells desensitizes the receptor-in-
duced decrease of cAMP level without a¡ecting its ability to
internalize.
2. Materials and methods
2.1. Materials
Somatostatin-14 (SRIF) and Tyr0-[D-Trp8]-SRIF were from Penin-
sula Laboratories. Tyr0-[D-Trp8]-SRIF was iodinated and puri¢ed as
described previously [3]. pcDNA3 plasmids containing the L-arrestin-1
or the deleted L-arrestin-1 (319^418) (v-arrestin-1) sequences were
generous gifts from Dr. Je¡rey L. Benovic (Philadelphia, PA, USA).
Ham F12 medium, geneticin and gentamicin were purchased from
Life Technologies; fetal calf serum was from Biowest; polyclonal
rabbit anti-c-myc and goat anti-L-arrestin-1 antibodies were from
Santa Cruz Biotechnology; FITC donkey anti-rabbit and Texas red
donkey anti-goat antibodies were from Molecular Probes. Forskolin,
isobutylmethylxanthine and pertussis toxin were from Sigma France;
transfection reagent DAC 30 was from Eurogentec, Seraing, Belgium.
2.2. Cell culture and transfection
CHO cells were grown in Ham F12 medium with 10% fetal calf
serum supplemented with gentamicin (50 Wg/ml). Cells were stably
transfected with the cDNA of the mouse sst2A receptor bearing a
N-terminal c-myc epitope in pcDNA3 (Invitrogen) using DAC 30.
Following selection with geneticin, a clone expressing 600 fmol/mg
of sst2A receptor was used for further experiments. Transient trans-
fections of L-arrestin-1 or v-arrestin-1 were performed using the
DEAE-dextran precipitation method [21]. The percentage of cells
that overexpress L-arrestin-1 or v-arrestin-1 was calculated to be
20^30% from confocal microscopic analysis. Membranes from non-
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transfected CHO cells were totally devoid of speci¢c [125I]Tyr0-[D-
Trp8]-SRIF binding.
2.3. Internalization experiments
Internalization experiments were performed on cells plated in
12-mm well culture dishes as previously described [3]. Brie£y, cells
were preincubated at 37‡C in the absence of drugs or with sucrose
(0.45 M) in an Earle’s Tris^HEPES bu¡er for 30 min. Cells were then
incubated with 0.3 nM [125I]Tyr0-[D-Trp8]-SRIF for various times and
washed twice with 0.5 ml of equilibration bu¡er, then twice with 0.5 ml
of an acid^NaCl bu¡er (Earle’s bu¡er titrated to pH 4 with acetic acid
and in which 0.5 M NaCl has been added) for 2 min to remove non-
sequestered radioactivity (acid^NaCl wash). Cells were harvested with
1 ml of 0.1 N NaOH and counted in a Q-counter. Non-speci¢c binding
was determined in the presence of 1 WM unlabeled SS14.
2.4. Recycling experiments
Cells were ¢rst incubated with 100 nM unlabeled SRIF for 15 min
at 37‡C to induce internalization. The peptide remaining on the cell
surface was removed by a series of ice-cold washes: three washes with
Earle’s Tris^HEPES bu¡er, two washes with 150 mM NaCl, 5 mM
acetic acid, and three more washes with Earle’s Tris^HEPES bu¡er.
Fresh Earle’s Tris^HEPES bu¡er was added and cells were incubated
at 37‡C for various times. In some cases, the medium was removed
and replaced by fresh medium every 5 min. The amount of cell surface
receptor was then measured in binding assays carried out with 0.5 nM
[125I]Tyr0-[D-Trp8]-SRIF for 30 min either at 37‡C in the presence of
the internalization blocker phenyl arsine oxide (PheAsO) or at 4‡C
without PheAsO. The non-speci¢c binding was determined in the
presence of 1 WM unlabeled SS14.
2.5. Western blot analysis
To control the expression level of L-arrestin-1 or v-arrestin-1 in
transfected cells, proteins from cell homogenates were separated on
a 12% polyacrylamide gel according to Laemmli [22], and transferred
on nitrocellulose membranes (0.2 Wm). Immunoblotting was per-
formed as previously described [23], using a 1:500 dilution of the
goat anti-L-arrestin-1 antibody which recognizes the C-terminus of
the protein, and revealed by the Lumilight enhanced chemilumines-
cence method (Roche Diagnostics).
2.6. Confocal microscopy experiments
CHO cells expressing the sst2A were transfected either with L-ar-
restin-1 or with the deleted L-arrestin-1 (319^418) (v-arrestin-1) and
grown on 12-mm coverslips. After preincubation for 10 min at 37‡C
in Earle’s Tris^HEPES bu¡er, cells were incubated in the presence or
in the absence of 10 nM SRIF at 37‡C for 5 min. After a rapid
washing step, cells were ¢xed with 4% paraformaldehyde in phos-
phate-bu¡ered saline (PBS) for 20 min at room temperature, washed
twice in PBS, then incubated with 50 mM NH4Cl in PBS for 10 min
to quench any excess of free aldehyde groups. Fixed cells were per-
meabilized by incubation in PBS containing 10% horse serum and
0.05% Triton X-100 for 20 min at room temperature, then incubated
with 1:500 dilution for the goat C-terminal anti-L-arrestin-1 polyclon-
al antibody and a 1:250 dilution of a rabbit anti-c-myc antibody in
PBS bu¡er containing 5% horse serum and 0.05% Triton X-100 for
1 h. Cells were rinsed three times in PBS bu¡er and incubated with a
FITC-conjugated donkey anti-rabbit antibody and a Texas red-con-
jugated donkey anti-goat antibody diluted 1:600 in PBS containing
5% horse serum and 0.05% Triton X-100 for 45 min. After two washes
with PBS and one wash with water, coverslips were mounted on glass
slides with Mowiol for confocal microscopy examination. Labeled
cells were visualized under a Leica laser scanning confocal microscope
(TCS-SP) equipped with a DM-IRBE inverted microscope and an
argon^krypton laser. Samples were scanned under both 488 nm and
647 nm excitation wavelengths. Images were acquired as single trans-
cellular optical sections and averaged over 16 scans/frame.
2.7. Measurement of cAMP content in CHO-sst2A cells
Cells grown in 35-mm dishes were incubated in complete Ham F12
medium with [3H]adenine (1 WCi/ml) for 18 h in the presence or in the
absence of pertussis toxin (100 ng/ml). Cells were preincubated in the
Earle’s Tris^HEPES bu¡er containing 1% bovine serum albumin and
0.2 mM isobutylmethylxanthine for 30 min at 37‡C, then incubated
for 30 min in the same bu¡er containing forskolin (10 WM) and in-
creasing concentrations of SRIF. The reaction was stopped by remov-
ing the medium and adding 500 Wl of ice-cold 5% trichloroacetic acid,
2 mM ATP and 2 mM cAMP for 15 min at 4‡C.
For desensitization experiments, the preincubation step was per-
formed in the presence of 100 nM SRIF, followed by two acid washes
for 2 min and one wash with the incubation bu¡er before incubation
with forskolin and SRIF. The tritiated cAMP content was measured
by chromatography on Dowex 50W-X8 columns as previously de-
scribed [24].
3. Results
3.1. Internalization properties of the sst2A in CHO cells
In order to determine the role of L-arrestin-1 on the inter-
nalization of [125I]Tyr0-[D-Trp8]-SRIF in CHO cells expressing
the N-terminal c-myc-tagged sst2A receptor, we measured the
amount of iodinated ligand sequestered at 37‡C on whole cells
under various experimental conditions. Preliminary experi-
Fig. 1. E¡ects of sucrose, pertussis toxin and L-arrestin-1 or v-ar-
restin-1 overexpression on the level of sst2A internalized into stable
c-myc-tagged sst2A transfected-CHO-cells. A: In the control experi-
ment (CON) the amount of SRIF internalized into sst2A-transfected
CHO cells was measured after 30 min. The e¡ects of sucrose, per-
tussis toxin (PTX), and L-arrestin-1 (L-arr1) or v-arrestin-1 (v-arr)
cotransfection are shown. Data represent the means þ S.E.M. of
three to ¢ve independent experiments. B: Western blot analysis of
the overexpression of L-arrestin-1 (lane 2, L) and v-arrestin-1 (lane
1, v) as compared to non-transfected CHO cells (lane 3, NT). Top
arrowhead indicates L-arrestin-1 overexpression, bottom arrowhead
shows the expression of v-arrestin-1.
Fig. 2. Time course of c-myc-tagged sst2A receptor recycling. A:
After induction of receptor sequestration for 15 min with 100 nM
SRIF, the peptide was removed by acid washes and cells were incu-
bated either with fresh medium for indicated times at 37‡C (closed
circles) or with fresh medium changed every 5 min up to indicated
times at 37‡C (open circles). The amount of cell surface receptor
was then determined as described in Section 2. B: The same experi-
ments carried out on cells cotransfected with L-arrestin-1 (closed
squares) or with v-arrestin-1 (open squares). Data are mean-
s þ S.E.M. from at least two di¡erent experiments.
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ments have shown that the binding a⁄nity of the c-myc-
tagged sst2A receptor for [125I]Tyr0-[D-Trp8]-SRIF (0.3 nM)
was identical to that of the wild type receptor expressed in
CHO cells. Measurement of the radioactivity associated with
cells stably transfected with the sst2A after acid^NaCl wash
revealed that 72% of total [125I]Tyr0-[D-Trp8]-SRIF bound
after 40 min was sequestered (Fig. 1A). The internalization
process was e⁄ciently inhibited by hyperosmolar sucrose
(Fig. 1A). Further transfection of these cells with either
L-arrestin-1 or its dominant negative v-arrestin-1 did not
modify the amount of internalized ligand (Fig. 1A). Pretreat-
ment of cells with pertussis toxin was without e¡ect on the
level of sst2A internalization (Fig. 1A). Overexpression of
both L-arrestin-1 and its dominant negative v-arrestin-1 was
veri¢ed by Western blotting of transfected cell extracts (Fig.
1B). The percentage of cells transfected with L-arrestin-1 con-
structs was calculated to be approximately 20^30% in all
cases.
3.2. Receptor recycling
We wanted to know whether the sst2A receptor was able to
recycle to the cell surface after internalization. Measurement
of reappearance of the receptor to the plasma membrane after
activation of the sequestration process with SRIF clearly
showed that most of the internalized receptors remained intra-
cellular up to 60 min (Fig. 2A). Washing out the medium
every 5 min during the recycling incubation did not modify
the absence of recycling of the sst2A receptor (Fig. 2A). This
result indicates that the sst2A does not recycle e⁄ciently and
rapidly to the plasma membrane. When experiments were
Fig. 3. Immunolocalization of c-myc-tagged sst2A and L-arrestin-1 in transfected CHO-sst2A cells. CHO cells expressing c-myc-tagged sst2A
were transiently transfected with L-arrestin-1 or v-arrestin-1 and either immediately ¢xed (A^C and G^I) or treated with 100 nM SRIF at 37‡C
for 5 min prior to ¢xation (D^F and J^L). Anti-c-myc FITC labeling (A, D, G, J) and labeling of anti-C-terminal L-arrestin-1 which recognize
both L-arrestin-1 (B and E) and v-arrestin-1 (H and K) revealed with Texas red-conjugated donkey anti-goat antibody are illustrated. Overlays
of FITC-c-myc-sst2A and L-arrestin-1 £uorescent labeling are shown in C and F. The yellow color indicates colabeling. Arrowheads show clus-
ters of colabeling. Overlays of FITC-c-myc-sst2A and v-arrestin-1 £uorescent labeling are shown in I and L. Scale bar: 10 Wm.
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carried out on CHO cells co-transfected with either L-arrestin-
1 or the dominant negative v-arrestin-1, no more recycling of
internalized sst2A receptor was observed (Fig. 2B). We also
checked that the amount of [125I]Tyr0-[D-Trp8]-SRIF released
in the medium during the recycling incubation never exceeded
10% of the total amount of sequestered radioactive ligand
(not shown). This amount of recycled ligand is much too
low to induce a signi¢cant modi¢cation of the cell surface
receptor.
3.3. Colocalization of sst2A and L-arrestin-1
Fluorescence immunolabeling of L-arrestin-1 and sst2A in
cotransfected CHO-cells is shown in Fig. 3. In the absence of
SRIF, the receptor was essentially localized at the cell surface
(Fig. 3A). Following 5 min of incubation with SRIF, sst2A
receptor immunolabeling was clearly translocated from the
cell surface to intracellular endosomal compartments (Fig.
3D). In the absence of peptide, the labeling obtained in cells
overexpressing L-arrestin-1 was di¡use throughout the cyto-
plasm (Fig. 3B) and remained intracellular following SRIF
activation (Fig. 3E). Merge imaging of both labels clearly
showed a colocalization of the receptor with L-arrestin-1 in
some intracellular endosomal vesicles only after stimulation
with SRIF (Fig. 3F). In cells overexpressing v-arrestin-1, no
colocalization was observed with the sst2A receptor (Fig.
3I,L) whatever the conditions, although the SRIF-induced
internalization of the c-myc-tagged receptor in endosomal
compartments was clearly maintained (Fig. 3J).
3.4. Desensitization of sst2A receptor, role of L-arrestin-1
The ability of SRIF to inhibit the forskolin-induced in-
crease of cAMP level was ¢rst measured in CHO cells express-
ing the sst2A with or without preincubation with 100 nM of
peptide. SRIF inhibited dose-dependently the forskolin-stimu-
lated cAMP level with a maximal e¡ect (45% inhibition) at
100 nM (Fig. 4A). Transfection of either L-arrestin-1 or v-
arrestin-1 did not modify SRIF inhibition of cAMP level (not
shown). When cells were pretreated for 30 min in the presence
of 100 nM SRIF and washed, forskolin remained able to
stimulate cAMP formation but SRIF could no longer de-
crease the forskolin-stimulated levels of cAMP. This result
demonstrates that the coupling of sst2A to adenylate cyclase
was desensitized by preincubation with the peptide. In CHO-
sst2A cells transfected with L-arrestin-1, the receptor desensi-
tization was maintained, since no SRIF inhibitory e¡ect was
observed after preincubation of transfected cells with the pep-
tide (Fig. 4B). By contrast, in CHO-sst2A cells transfected
with v-arrestin-1, SRIF kept its ability to inhibit forskolin
stimulation of cAMP even after pretreatment with 100 nM
SRIF (Fig. 4B), indicating that desensitization of sst2A by
SRIF was prevented by v-arrestin-1.
4. Discussion
The present study con¢rms the existence of an interaction
between L-arrestin-1 and the sst2A receptor after activation
by SRIF and demonstrates that this interaction is crucial for
desensitization but not for internalization of the receptor.
Evidence for arrestin involvement on agonist-mediated de-
sensitization of endogenous SRIF receptors has been previ-
ously shown in HEK293 cells in which reduction of arrestin
levels attenuated desensitization of SRIF receptor [20]. How-
ever, in HEK293 cells, the subtype of SRIF receptor that was
regulated by arrestins had not been identi¢ed [20], although it
had been reported earlier that the sst2A receptor was ex-
pressed at low levels in HEK cells [25]. Here, we show that
SRIF activation induces a cellular translocation of L-arrestin-
1 from a di¡use cytoplasmic location to vesicular endosomal
compartments also containing the sst2A receptor. Previous
studies have indicated that arrestins can tra⁄c with some in-
ternalized GPCRs into early endosomes [26,27]. However, in
the case of sst2A receptor, the association with L-arrestin-1 is
not essential since we demonstrate here that overexpression of
either L-arrestin-1 or v-arrestin-1 does not a¡ect receptor in-
ternalization. An arrestin-independent internalization process
has already been described for the m1, m3 and m4 subtypes of
muscarinic cholinergic receptors [28]. By contrast, the L-ar-
restin-1-sst2A interaction appears crucial for receptor desensi-
tization, since transfection of v-arrestin-1 which disrupts the
interaction between endogenous arrestins and clathrin totally
abolishes sst2A desensitization.
SRIF-induced sst2B receptor desensitization has been sug-
gested to be dependent on receptor internalization in the neu-
roblastomaUglioma hybrid cell line NG108-15, although this
process was shown to be independent of the GRKs [29]. All
these data suggest that the interaction of L-arrestin with a
GPCR upon ligand activation is observed in almost all cases
but that this interaction may be either passive (i.e. for mus-
carinic m1 and sst2A) or active (i.e. for L2-adrenergic) to-
wards the receptor internalization process. By contrast, even
if this interaction is ine¡ective on receptor internalization, it
may contribute to desensitization. Although a prolonged
L-arrestin^GPCR interaction has been shown to be responsi-
ble for the absence of rapid receptor recycling for the vaso-
pressin V2 receptor [30], this is not the case for the sst2A
receptor. Even in the absence of interaction with arrestin,
i.e. in the presence of v-arrestin-1, no recycling of receptor
was observed (Fig. 2B). The inability of the sst2A to rapidly
recycle in AtT20 cells was already observed by £uorescence
immunocytochemistry. After prolonged stimulation of AtT20
cells with SRIF, the labeling of the receptor was concentrated
in the cytoplasmic core next to the nucleus, whereas the cell
surface immunolabeling was almost totally lost [24]. The fact
that the receptor has lost its ability to be desensitized in the
Fig. 4. E¡ects of L-arrestin-1 and v-arrestin-1 on SRIF-induced ac-
tivation and desensitization in CHO-c-myc-sst2A cells. A: Concen-
tration-dependent inhibition of forskolin (100 WM)-stimulated cAMP
level in CHO-sst2A cells by SRIF with 30 min pretreatment of cells
(squares) or without 30 min pretreatment of cells (circles) with 100
nM SRIF. B: E¡ects of L-arrestin-1 (L-arr) or v-arrestin-1 (v-arr)
transfection on SRIF-induced desensitization in CHO-sst2A cells.
Data are means þ S.E.M. from at least three independent experi-
ments.
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presence of the dominant negative v-arrestin-1 although a
large proportion of receptor was sequestered suggests that
the desensitization induced by L-arrestin-1 binding mainly in-
volves cell surface sst2A receptor. This also indicates that the
two processes are dissociated and that internalization is not a
prerequisite for desensitization. In the same way, recycling
and desensitization are likely not strictly interconnected for
the sst2A receptors. Although L-arrestin-1 was colocalized
with internalized receptors and was described to bind recep-
tors involved in the desensitization, this interaction is certainly
no longer essential for receptor sequestration for which L-ar-
restin-1 could be replaced by other component(s) of the endo-
cytotic machinery. By contrast, this interaction is crucial for
homologous desensitization of sst2A receptors.
In conclusion, we have shown that L-arrestin-1 interacts
with the mouse somatostatin receptor subtype sst2A and
that this interaction is a necessary prerequisite for receptor
desensitization. By contrast, the L-arrestin-1-sst2A interaction
is not essential for intracellular sequestration of the SRIF^
receptor complex. Thus, di¡erent intracellular protein part-
ners are involved in the mechanisms of internalization and
desensitization of GPCRs.
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